Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardClinical Forum InsightsInsightsMedcastPeers & Perspectives
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Martin G. Sanda, MD

Advertisement

Articles by Martin G. Sanda, MD

Prostate cancer treatments: Assessing effects on quality of life

ByAndrew A. Wagner, MD,Martin G. Sanda, MD
September 1st 2006

The most instructive HRQoL studies are those that rely on prospective, longitudinal assessments of patients using a validated instrument.

Advertisement

Latest Updated Articles

  • Prostate cancer treatments: Assessing effects on quality of life
    Prostate cancer treatments: Assessing effects on quality of life

    Published: September 1st 2006 | Updated:



Advertisement
Advertisement

Trending on Urology Times

1

Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing

2

Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC

3

Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer

4

Amanda North, MD, recaps SWIU 2026 session on imposter syndrome

5

Docetaxel plus tumor-targeting IL-12 yields promising activity in mCRPC

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us